What's in NURIA LLOBERAS BLANCH's pipeline?

NURIA LLOBERAS BLANCH has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with NURIA LLOBERAS BLANCH's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nuria-lloberas-blanch.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

NURIA LLOBERAS BLANCH — Portfolio Competitive Intelligence Brief

NURIA LLOBERAS BLANCH pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Standard dosage of Tacrolimus	Standard dosage of Tacrolimus	marketed
Bayesian Prediction Tacrolimus dosage	Bayesian Prediction Tacrolimus dosage	marketed			Immunology

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for NURIA LLOBERAS BLANCH:

Cite this brief

Drug Landscape (2026). NURIA LLOBERAS BLANCH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nuria-lloberas-blanch. Accessed 2026-05-16.